CLI-05993AA5-06: A 52 week study in which neither Sponsor or participant know the treatment assigned to subjects to compare the experimental drug (CHF 5993) with a commercial drug (Seretide Evohaler) in adolescent subjects with treated uncontrolled asthma (clinicaltrialsregister.eu) - Feb 18, 2026 - P2/3 | N=147 | Not yet recruiting | Sponsor: Chiesi Farmaceutici S.p.A.
New P2/3 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
|